Factor XI (FXI) has emerged as a promising target in the prevention and treatment of venous and arterial thromboembolism in several clinical settings. Its pharmacological inhibition, through small molecules, monoclonal antibodies, antisense oligonucleotides an... ...

请注册登录后继续浏览